Upstream Bio (NASDAQ:UPB) Reaches New 1-Year High – Should You Buy?

Upstream Bio, Inc. (NASDAQ:UPB) reached a new 52-week high on Wednesday . The stock traded as high as $33.28 and last traded at $32.5990, with a volume of 46309 shares trading hands. The stock had previously closed at $32.60.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Evercore ISI started coverage on shares of Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective for the company. Lifesci Capital began coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price on the stock. Truist Financial started coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They set a “buy” rating and a $47.00 target price on the stock. Finally, Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.25.

Upstream Bio Stock Up 2.5%

The business has a 50 day moving average price of $27.35 and a 200 day moving average price of $20.72. The stock has a market cap of $1.81 billion, a P/E ratio of -17.78 and a beta of 1.90.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. The firm had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.65 million. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. On average, research analysts expect that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

A number of hedge funds have recently added to or reduced their stakes in UPB. AQR Capital Management LLC acquired a new stake in Upstream Bio during the first quarter worth about $115,000. Woodline Partners LP lifted its holdings in Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after acquiring an additional 30,552 shares during the period. CWM LLC lifted its holdings in Upstream Bio by 107.5% in the second quarter. CWM LLC now owns 3,312 shares of the company’s stock valued at $36,000 after acquiring an additional 1,716 shares during the period. Geode Capital Management LLC boosted its holdings in Upstream Bio by 57.5% during the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after buying an additional 235,958 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Upstream Bio by 133.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock valued at $86,000 after acquiring an additional 4,483 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.